MBBS, FRCSEd (General Surgery), FRCSGlasg (General Surgery), FRCSEd (Neurosurgery), FAMS (Neurosurgery)
Dr. Christopher Beng-Ti Ang trained in neurosurgery at the National Neuroscience Institute (NNI), Singapore and at the University of British Columbia in Vancouver, Canada. During his residency, he carried out bench research defining the molecular mechanisms in oligodendrocyte development and myelination, with notable publications in Cell, EMBO J and J Biol Chem.
He is currently a senior consultant neurosurgeon and Head of Neurosurgery at the Singapore General Hospital with a sub-specialty practice in endonasal skull base surgery and radiosurgery. He co-ordinates the multi-disciplinary pituitary tumor service which brings together the varied specialties of neurosurgery, rhinology, neuro-ophthalmology, endocrinology and radiation oncology.
He also co-directs the Neuro-Oncology Research Lab where the primary focus is defining precision medicine strategies for the treatment of malignant gliomas, with work having been published in Cancer Res, Clin Cancer Res, Stem Cells, J Natl Cancer Inst and Nat Comms. In addition, he is an Associate Professor at the Duke-National University of Singapore Medical School, where he contributes to the Brain and Behaviour programme.
Professional Appointments and Committee Memberships:
- Board Member, Chapter of Neurosurgeons, Academy of Medicine, Singapore
- Member, RAC (Neurosurgery), Joint Committee on Specialist Training
- Clinician-Scientist Award (Investigator Category), National Medical Research Council, Singapore (2017)
- Clinician-Scientist Award (Investigator Category), National Medical Research Council, Singapore (2014)
- SingHealth GCEO Excellence Award: Outstanding Clinician Researcher, 2013
- Pioneer Award, Duke-National University of Singapore Graduate Medical School, 2011
Research Interests: Precision medicine in Neuro-Oncology
Tan MSY, Sandanaraj E, Chong YK, Lim SW, Koh LWH, Ng WH, Tan NS, Tan P, Ang BT*, Tang C*. A STAT3-based gene signature stratifies glioma patients for targeted
therapy. Nat Commun. 2019 Aug 9;10(1):3601.
Xu L, Chen Y, Mayakonda A, Koh L, Chong YK, Buckley DL, Sandanaraj E, Lim SW, Lin RY, Ke XY, Huang ML, Chen J, Sun W, Wang LZ, Goh BC, Dinh HQ, Kappei D,Winter GE, Ding LW, Ang BT, Berman BP, Bradner JE, Tang C, Koeffler HP.
Targetable BET proteins- and E2F1-dependent transcriptional program maintains themalignancy of glioblastoma. Proc Natl Acad Sci U S A. 2018 May
Chong YK, Sandanaraj E, Koh LW, Thangaveloo M, Tan MS, Koh GR, Toh TB, Lim GG,Holbrook JD, Kon OL, Nadarajah M, Ng I, Ng WH, Tan NS, Lim KL, Tang C*, Ang BT*. ST3GAL1-Associated Transcriptomic Program in Glioblastoma Tumor Growth, Invasion,and Prognosis. J Natl Cancer Inst. 2015 Nov 7;108(2).
Li S, Wang C, Sandanaraj E, Aw SS, Koe CT, Wong JJ, Yu F, Ang BT, Tang C, Wang H. The SCFSlimb E3 ligase complex regulates asymmetric division to inhibit neuroblast overgrowth. EMBO Rep. 2014 Feb;15(2):165-74.
Koh LW, Koh GR, Ng FS, Toh TB, Sandanaraj E, Chong YK, Phong M, Tucker-Kellogg G, Kon OL, Ng WH, Ng IH, Clement MV, Pervaiz S, Ang BT*, Tang CS*. A distinct reactive oxygen species profile confers chemoresistance in glioma-propagating cells and associates with patient survival outcome. Antioxid Redox Signal. 2013 Dec 20;19(18):2261-79.
Choudhury Y, Tay FC, Lam DH, Sandanaraj E, Tang C, Ang BT, Wang S. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest. 2012 Nov;122(11):4059-76
Ng FS, Toh TB, Ting EH, Koh GR, Sandanaraj E, Phong M, Wong SS, Leong SH, Kon OL, Tucker-Kellogg G, Ng WH, Ng I, Tang C*, Ang BT*. Progenitor-like traitscontribute to patient survival and prognosis in oligodendroglial tumors. Clin
Cancer Res. 2012 Aug 1;18(15):4122-35.
Chong YK, Toh TB, Zaiden N, Poonepalli A, Leong SH, Ong CE, Yu Y, Tan PB, See SJ, Ng WH, Ng I, Hande MP, Kon OL, Ang BT*, Tang C*. Cryopreservation of neurospheres derived from human glioblastoma multiforme. Stem Cells. 2009